Breast cancer treatment technology provider Devicor Medical Products and Faxitron Bioptics have announced a new distribution agreement.
Devicor will now distribute Faxitron's CoreVision core specimen radiography system, which is marketed to breast radiologists and surgeons. The device verifies the presence of microcalcifications in core biopsies, confirming a successful biopsy procedure directly in the stereotactic biopsy suite, according to the firm.
The agreement includes the newly cobranded Mammotome CoreVision within the U.S., with pending distribution in other countries in Europe and Asia, Devicor said.
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
